Efficacy
PD, tumor, BOR, PD‐L1
BRAIN METASTASIS, TUMOR, DISEASE, BEST, LIVER METASTASIS
In the ITT population, the majority of patients (61.9%) had a reduction in tumor burden (Figure (A) Best change from baseline in sum of target lesion diameters, according to type of Change from baseline in sum of target lesion diameters over time. Three patients had a BOR of PD; two patients had a change from baseline in target lesion diameters of 24% over 6 weeks, so these data points overlap on the plot. BOR, best overall response; PD, progressive disease; PR, partial response; SD, stable disease.The median PFS was 7.0 months (95% CI, 5.4–8.6), with a 6‐month PFS rate of 57.1% (95% CI, 33.8–74.9) and a 12‐month PFS rate of 22.2% (95% CI, 7.4–42.0; Figure Progression‐free survival (PFS) overall and overall survival (OS) overall and in subgroups of interest. Kaplan–Meier plots indicating: (A) PFS among all patients; (B) OS among all patients; (C) PFS for patients with (red trace) or without (blue trace) brain metastasis; (D), PFS for patients with (red trace) or without (blue trace) liver metastasis.A univariate analyses showed no statistically significant association between PFS and PD‐L1 expression or the presence of CD4+, CD8+, Foxp3+, CD163+, and LAG3+ immune cells (Figure (A) Univariate analysis of progression‐free survival according to baseline patient characteristics; (B) Univariate analysis of overall survival according to baseline patient characteristics.